US President Joe Biden receives a second booster shot of the Pfizer Covid-19 vaccine in the South Court Auditorium, next to the White House, in Washington, DC, on 30 March 2022.
- A new Covid vaccine’s release in the US is imminent and experts predict it
may not be well-received.
- Healthcare providers will start offering the updated vaccine next month to
fight the Omicron variant.
- Covid-19 vaccine makers have lowered their expectations for this Autumn’s
A new Covid vaccine is due out next month, but health experts and analysts
say it is likely to be coolly received even as hospitalisations from
“Eris”, a variant of the Omicron form of the coronavirus, rise around
Some public health experts hope that Americans will welcome the new shot
as they would a flu jab. But demand for the vaccine has dropped sharply since
2021 when it first became available and more than 240 million people in the US,
or 73% of the population, received at least one shot.
In the fall of 2022, by which time most people had either had the Covid
virus or the vaccine, fewer than 50 million people got the shots.
Healthcare providers and pharmacies such as CVS Health will start next
month to offer the shot, updated to fight the Omicron version of the virus that
has been dominant since last year.
They will be fighting declining concern about the virus, as well as
fatigue and skepticism about the merits of this vaccine, Kaiser Family
Foundation Director of Survey Methodology Ashley Kirzinger said.
“Public health officials, if they want to see a majority of adults
get these annual vaccines, they’re going to have to make the case to the
American public that Covid isn’t over and it still poses a risk to them,”
The top reason vaccinated people gave in KFF surveys earlier this year for
eschewing annual shots was they believed they had protection from the virus
because of previous shots or infections, she said.
Covid-19 vaccine makers have pared back expectations for this fall’s
vaccination campaign, with Pfizer – the largest maker of mRNA shots with
BioNTech – recently warning that it might need to cut jobs if it does not do
well. Its biggest rival, Moderna, conceded demand could be as few as 50 million
ALSO READ | Living with long Covid
Last year, Pfizer and Moderna’s vaccine sales topped $56 billion
worldwide; analysts project around $20 billion for this year.
Jefferies analyst Michael Yee said he does not expect the autumn campaign
to reach last year’s.
Take a look at what happened last winter. It was 50 million in the US, and it seems likely to be lower than that, given that there’s less concern about Covid this year than last year.
Post pandemic vaccine
The Covid public health emergency ended in May and the government has
handed much of the duty of vaccinating America to the private sector. Over 1.1
million people in the United States have died from Covid, according to the U.S.
Centers for Disease Control and Prevention (CDC).
CDC Director Mandy Cohen said last week in a podcast that she expects the
shots – which still need to be authorized by the U.S. Food and Drug
Administration and recommended by the CDC – to be rolled out in the third or
fourth week of September. She suggested Americans should view these shots as an
annual measure to protect oneself, in line with the annual flu shot.
As with the flu, Pfizer/BioNTech SE, Moderna and Novavax, have created
versions of the Covid vaccine to try to match the variant they believe will be
circulating this fall. The shots are aimed at XBB.1.5, a subvariant that is
similar to EG.5 and also a sub-lineage of the still dominant Omicron variant.
Covid-19-related hospitalisations are up more than 40% off of recent lows
hit in June, but are still more than 90% below peak levels hit during the
January 2022 Omicron outbreak, according to CDC data.
Some doctors suggest that annual shots should be targeted at the elderly
and other high-risk people, who are most likely to have dire outcomes if they
Dr. William Schaffner, an infectious diseases specialist at Vanderbilt
University and a liaison to the CDC’s Advisory Committee on Immunization
practices, said it is possible that the ACIP could make a weaker recommendation
for younger, healthier people. That could also affect demand.
“Should children really receive this booster?” Schaffner said. “Should
the average person with no underlying illness who is a younger adult receive
this vaccine or should this vaccine now be a more targeted vaccine?”
The CDC recommended children get a single dose of last year’s updated
vaccine for those aged 6 and older.
Dr. David Boulware, an infectious diseases specialist at the University of
Minnesota, said that according to research he has published, people who are
boosted have less severe symptoms for a shorter duration.
“When you look at what you can do to reduce your duration of illness,
even if you do get sick, being boosted is going to be the best way to do
that,” he said.